Oral News and Research

RSS

Mexiletine use improves stiffness in patients with nondystrophic myotonias

Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the anti-arrhythmic medication mexiletine resulted in improvement in patient-reported stiffness, according to a preliminary study in the October 3 issue of JAMA.

3 Oct 2012

Positive results from Noven’s LDMP Phase 3 clinical studies on menopausal VMS

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced positive results from two multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

3 Oct 2012

October issue of WHO Bulletin available online

The October issue of the WHO Bulletin features an editorial on the stockpiling oral cholera vaccine, a public health news roundup, a research article on rotavirus mortality in India, and an article examining a "new entity for the negotiation of public procurement prices for patented medicines in Mexico," among others.

2 Oct 2012

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of overall survival (OS) data from the trastuzumab emtansine Phase III trial, EMILIA.

2 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

1 Oct 2012

Crizotinib effectively treats patients with ALK-positive lung cancer

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Sorafenib does not improve overall survival among patients with NSCLC

Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. However, a post-hoc biomarker analysis of the trial data that was also presented suggests that patients with EGFR-mutant tumors may benefit.

29 Sep 2012

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012.

29 Sep 2012

FDA approves Stiefel’s Sorilux Foam sNDA to treat for scalp psoriasis

Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005%. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psoriasis of the scalp in patients aged 18 years and older.

29 Sep 2012

UBM Live announces finalists of CPhI Pharma Awards

Leading events organiser, UBM Live, announced the finalists of the CPhI Pharma Awards. Formerly known as the Innovation Awards, the rebranded CPhI Pharma Awards feature a gold, silver and bronze winner for the returning Best Pharma Innovation award.

29 Sep 2012

IADR/AADR publish study about improving oral health through sense of coherence

Today, the International and American Associations for Dental Research (IADR/AADR) published a study titled "Enhancing Oral Health via Sense of Coherence: a Cluster Randomized Trial." This study by lead author Orawan Nammontri, University of Sheffield, UK, is published in the IADR/AADR Journal of Dental Research.

28 Sep 2012

Tianyin Pharmaceutical sales decrease 26.9% to $69.6 million for fiscal year 2012

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2012.

28 Sep 2012

Two-part ACR guidelines on gout

Gout is one of the most common forms of inflammatory arthritis, affecting nearly 4% of adult Americans. Newly approved guidelines that educate patients in effective methods to prevent gout attacks and provide physicians with recommended therapies for long-term management of this painful disease are published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR).

28 Sep 2012

Story describes need for male version of oral contraceptive pills

When will men have their own birth control pill? Scientists have been predicting the debut of a male pill within 5 years for the last 30 years. The factors accounting for that delay - and new optimism that a male pill will emerge within a decade - are the topic of a story in the current edition of Chemical & Engineering News. C&EN is the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

27 Sep 2012

Aeterna Zentari expects to file AEZS-130 NDA with FDA for adult growth hormone deficiency

Aeterna Zentaris Inc. today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD), after receiving notification from the United States Food and Drug Administration (FDA) that Fast Track designation had not been granted.

27 Sep 2012

Novel oral anticoagulant bleeding risk offsets clinical benefit

The use of orally activated Xa antagonist and direct thrombin inhibitors is associated with a significant increase in major bleeding events in acute coronary syndrome patients, a study shows.

27 Sep 2012

Oral News and Research

Mexiletine use improves stiffness in patients with nondystrophic myotonias

Positive results from Noven’s LDMP Phase 3 clinical studies on menopausal VMS

October issue of WHO Bulletin available online

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Crizotinib effectively treats patients with ALK-positive lung cancer

Sorafenib does not improve overall survival among patients with NSCLC

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

FDA approves Stiefel’s Sorilux Foam sNDA to treat for scalp psoriasis

UBM Live announces finalists of CPhI Pharma Awards

IADR/AADR publish study about improving oral health through sense of coherence

Tianyin Pharmaceutical sales decrease 26.9% to $69.6 million for fiscal year 2012

Two-part ACR guidelines on gout

Story describes need for male version of oral contraceptive pills

Aeterna Zentari expects to file AEZS-130 NDA with FDA for adult growth hormone deficiency

Novel oral anticoagulant bleeding risk offsets clinical benefit

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News